Protein kinase Cη activates NF-κB in response to camptothecin-induced DNA damage

Biochemical and Biophysical Research Communications

Volumn 412, Issue 2, 2011, Pages 313-317

  Raveh Amit, Hadas ^a   Hai, Naama ^a   Rotem Dai, Noa ^a   Shahaf, Galit ^a   Gopas, Jacob ^a,b   Livneh, Etta ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Camptothecin; DNA damage; Nuclear factor B transactivation; Protein kinase C; RelA P65

Indexed keywords

CAMPTOTHECIN; DNA; I KAPPA B; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN KINASE C ETA;

ARTICLE; CONTROLLED STUDY; DNA DAMAGE; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE TRANSLOCATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN INDUCTION; SIGNAL TRANSDUCTION; TRANSACTIVATION;

ACTIVE TRANSPORT, CELL NUCLEUS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CELL LINE, TUMOR; CELL NUCLEUS; DNA DAMAGE; DRUG RESISTANCE, NEOPLASM; HUMANS; NF-KAPPA B; PROTEIN KINASE C; TRANSCRIPTION FACTOR RELA;

EID: 80052037206     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.07.090     Document Type: Article

References (23)

1. Aggarwal B.B. Nuclear factor-kappaB: the enemy within. Cancer Cell 2004, 6:203-208.
2. Escarcega R.O., Fuentes-Alexandro S., Garcia-Carrasco M., Gatica A., Zamora A. The transcription factor nuclear factor-kappa B and cancer. Clin. Oncol. (R Coll. Radiol.) 2007, 19:154-161.
3. Nakanishi C., Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat. Rev. Cancer 2005, 5:297-309.
4. Baud V., Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat. Rev. Drug Discov. 2009, 8:33-40.
5. Janssens S., Tschopp J. Signals from within: the DNA-damage-induced NF-kappaB response. Cell Death Differ. 2006, 13:773-784.
6. Mackay H.J., Twelves C.J. Targeting the protein kinase C family: are we there yet?. Nat. Rev. 2007, 7:554-562.
7. Mellor H., Parker P.J. The extended protein kinase C superfamily. Biochem. J. 1998, 332:281-292.
8. Nishizuka Y. Protein kinase C and lipid signaling for sustained cellular responses. FASEB J. 1995, 9:484-496.
9. Abu-Ghanem S., Oberkovitz G., Benharroch D., Gopas J., Livneh E. PKCη expression in Hodgkin's lymphoma cell lines confers resistance to apoptosis. Cancer Biology and Therapy. 2007, 6:1375-1380.
10. Rotem-Dai N., Oberkovitz G., Abu-Ghanem S., Livneh E. PKCeta confers protection against apoptosis by inhibiting the pro-apoptotic JNK activity in MCF-7 cells. Exp. Cell Res. 2009, 315:2616-2623.
11. Sonnemann J., Gekeler V., Ahlbresht K., Brischwein K., Liu C., Bader P., Muller C., Niethammer D., Beck J.F. Down-regulation of protein kinase Cη by antisense oligonucletides sensitises A549 lung cancer cells to vincristine and paclitaxel. Cancer Lett. 2004, 209:177-185.
12. Hussaini I.M., Carpenter J.E., Redpath G.T., Sando J.J., Shaffrey M.E., VandenBerg S.R. Protein kinase C-η regulates resistance to UV and γ-irradiation-induced apoptosis in glioblastoma cells by preventing caspase-9 activation. Neuro-Oncol. 2002, 4:9-21.
13. Matsumura M., Tanaka N., Kuroli T., Ichihashi M., Ohba M. The cisoform of protein kinase C inhibits UV-induced activation of caspase 3 in normal human keratinocytes. Biochem. Biophys. Res. Commun. 2003, 303:350-356.
14. Fima E., Shtutman M., Libros P., Missel A., Shahaf G., Kahana G., Livneh E. PKCη enhanced cell cycle progression, the expression of G1 cyclins and p21 in MCF-7 cells. Oncogene 2001, 20:6794-6804.
15. Chen B., Przybyla A.E. An efficient site-directed mutagenesis method based on PCR. Biotechniques 1994, 17:657-659.
16. Raveh-Amit H., Maissel A., Poller J., Marom L., Elroy-Stein O., Shapira M., Livneh E. Translational Control of Protein Kinase C{eta} by Two Upstream Open Reading Frames (uORFs). Mol. Cell Biol. 2009, 23.
17. Maissel A., Marom M., Shtutman M., Shahaf G., Livneh E. PKCη is localizes in the Golgi, ER and nuclear envelope and translocates to the nuclear envelope upon PMA activation and serum-starvation: C1b domain and the pseudosubstrate containing fragment target PKCη to the Golgi and the nuclear envelope. Cellular Signalling 2006, 18:1127-1139.
18. Pereira S.G., Oakley F. Nuclear factor-kappaB1: regulation and function. Int. J. Biochem. Cell Biol. 2008, 40:1425-1430.
19. Huang T.T., Wuerzberger-Davis S.M., Seufzer B.J., Shumway S.D., Kurama T., Boothman D.A., Miyamoto S. NF-kappaB activation by camptothecin. A linkage between nuclear DNA damage and cytoplasmic signaling events. J. Biol. Chem. 2000, 275:9501-9509.
20. Tamarkin A., Zurgil U., Braiman A., Hai N., Krasnitsky E., Maissel A., Ben-Ari A., Yankelovich L., Livneh E. DNA damage targets PKCh to the nuclear membrane via its C1B domain. Exp Cell Res. 2011, 10:1465-1475.
21. Basseres D.S., Baldwin A.S. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 2006, 25:6817-6830.
22. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell. 2011, 144:646-674.
23. Yamamoto K., Ichijo H., Korsmeyer S.J. BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol. Cell Biol. 1999, 19:8469-8478.